Intravesical Therapy With 5-Fu For Transitional Bladder Cancer Following TURBt

Objective An analysis was done to compare the prophylactic efficacy and treatment toxicity of intravesical therapy for primary superficial bladder cancer following TURBt on recurrence by 5-Fu,HCPT versus MMC.Methods Materials and Methods :95 cases of primary superficial transitional bladder cancer were treated by TURBt.After surgical management,intravesical instillation therapy with 5-Fu,HCPT or MMC was carried respectively.27 cases which refuse the intravesical therapy is the control group.Results 95 cases were followed up for 8 years. For different instillation groups, the average recurrent time is 30.1-31.3 months, 5-years living rate is 67.9%-78.5%.There is no significant difference between 5-Fu,HCPT and MMC group, while great significant difference between 5-Fu,HCPT or MMC with control group. Total treatment side effects rate is 23.1%-35.7%, mostly with low toxicity, which can be tolerance. The toxicity of 5-Fu group is higher than HCPT and MMC group, but without severe side effects.Conclusions Intravesical instillation of 5-Fu,HCPT or MMC is effective in preventing primary superficial bladder cancer from recurring after TURBt with great significant difference of the control group. Though the toxicity is higher, 5-Fu, with lower price as well as prefect efficacy, is still a prominent new drug of intravesical therapy, which should be studied further.